Galectins
| 6 min read
Immunologist Gabriel Rabinovich leverages his 30 years of experience studying sugar-binding proteins, galectins, for developing novel therapies.
Page 1 of 1 - 1 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Overcoming barriers in gene therapy
Advanced gene editing, delivery, and analytical tools are driving better gene therapies.
A multiomic approach to profiling brain tumors
Probing the molecular drivers of brain metastasis reveals novel therapeutic targets.
Enhancing immune cell profiling with digital technologies
Software innovations help researchers decode immune complexity in cancer.
